A new organ preservation solution for static cold storage of the liver. Amniotic fluid

Abstract

Purpose: To evaluate the effect of amniotic fluid in liver preservation in organ transplantation, and compare it with standard preservation solutions. Methods: The groups consisted of Group 1: Ringer Lactate (RL) group, Group 2: HTK group, Group 3: UW group, Group 4: AF group. The livers of rats from Group 1, 2, 3, and 4 were perfused and placed into falcon tubes containing RL, HTK, UW, and AF solutions at +4‎°C, respectively. The tubes were stored for 12 hours in the refrigerator at +4°C. Tissue samples were taken at the 6 th and 12 th hours for histopathological examinations of the perfused livers, and storage solutions for biochemical analyzes at 6 th and 12 th hours. Results: AF was shown to maintain organ viability by reducing the number of cells undergoing apoptosis. Histopathological changes such as sinusoidal dilatation, hydropic degeneration, and focal necrosis were found to be similar to the groups in which the standard organ preservation solutions were used. Additionally, the results of INOS, IL-10, and TNF-α,which were evaluated immunohistochemically, have been shown to be similar to the UW and HTK groups. Conclusions: AF provided conservation similar to UW and HTK in the 12-hour liver SCS process. The fact that apoptosis values are comparable to standard preservation solutions supports the success of AF in the cold storage of the liver.

Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities

“…In fact, organ preservation upon resection and prior to transplantation to the recipient remains a major challenge for transplant surgeons. A recent study published an innovative method for static cold storage of the liver using cfAF ( Figure 3 ) [ 79 ]. This comparative study observed that livers perfused with cfAF maintained organ viability to a level similar to the standard University of Wisconsin (UW) and Histidine-tryptophan-ketoglutarate (HTK) preservation solutions [ 79 ].…”

“…A recent study published an innovative method for static cold storage of the liver using cfAF ( Figure 3 ) [ 79 ]. This comparative study observed that livers perfused with cfAF maintained organ viability to a level similar to the standard University of Wisconsin (UW) and Histidine-tryptophan-ketoglutarate (HTK) preservation solutions [ 79 ]. Although these limited analyses produced findings similar to standard of care methods, this is a rational approach that requires further investigation.…”

External pressure dynamics promote kidney viability and perfusate filtration during ex vivo kidney perfusion

“…2 Department of Kidney Regenerative Medicine, Industry-Academia Collaborative Department, The Jikei University School of Medicine, Tokyo, Japan. 3 Tokaihit Co., Ltd., Shizuoka, Japan. * email: sekine.hidekazu@twmu.ac.jp However, it is difficult to perfectly reproduce circulation in vitro with NMP, because the circulation of the perfusing solutions is controlled only by a pump.…”

“…The immersion cooling preservation method is now commonly used in clinical practice because of the simplicity of the procedure and transportation. The permissible ischemia time before restarting blood flow once the organ has been harvested from the donor is 4 h for the heart 1 , 8 h for the lungs 2 , 12 h for the liver and small intestine 3 , 4 , and 24 h for the pancreas and kidneys 5 , 6 . Organ transplants from marginal donors, such as cardiac arrest donors or elderly donors, have gradually become mainstream in the recent years to increase the number of donor organs.…”

Comparative study between fructose 1-6 bisphosphate and histidine-tryptophan-ketoglutarate in liver preservation in rats submitted to total cold ischemia

“…Liver transplantation is used in situations in which patients with liver disease have a life expectancy of less than 20% at the end of 12 months, if they are not transplanted, and in those in which the risk of mortality exceeds the rate resulting from the transplant itself. It is considered a form of treatment for patients with terminal liver failure due to chronic cholestatic and hepatocellular liver diseases, metabolic and vascular liver diseases, primary liver tumor and trauma 1 , 2 . More than 10.000 liver transplants are performed worldwide per year 3 .…”